Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis

Emirates PharmaAdvertisement

Gilead Sciences, Inc.announced it is stopping ARTEMIS-IPF, the company’s ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy.

This decision follows an interim analysis of unblinded efficacy and safety data by the study’s Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan. Gilead is conducting a thorough review of the data and will communicate the full results of this analysis to the medical community when they are available.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Emirates PharmaAdvertisement